Allogene Therapeutics, Inc. (ALLO) Current Ratio
- Current ratio · latest quarter: Value 10.72×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 10.72× | Current assets / current liabilities. $340.00M ÷ $31.73M ≈ 10.72× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 340.00M USD | Assets, Current |
| Current obligations | 31.73M USD | Liabilities, Current |
| Cash and equivalents | 38.63M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 293.98M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 5.96M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $340.00M | $31.73M | $38.63M | $293.98M | (m) | (m) | $5.96M | (m) | 10.72× |
| 2026-03-31 | $273.29M | $28.33M | $30.31M | $236.58M | (m) | (m) | $4.93M | (m) | 9.65× |
| 2025-12-31 | $257.75M | $32.51M | $51.69M | $198.52M | (m) | (m) | $4.27M | (m) | 7.93× |
| 2025-09-30 | $260.72M | $31.83M | $37.81M | $214.38M | (m) | (m) | $3.70M | (m) | 8.19× |
| 2025-06-30 | $282.65M | $31.68M | $52.33M | $220.79M | (m) | (m) | $4.85M | (m) | 8.92× |
| 2025-03-31 | $291.58M | $30.02M | $42.45M | $237.59M | (m) | (m) | $5.06M | (m) | 9.71× |
| 2024-12-31 | $303.39M | $35.52M | $75.22M | $217.26M | (m) | (m) | $5.39M | (m) | 8.54× |
| 2024-09-30 | $304.42M | $32.57M | $51.24M | $240.32M | (m) | (m) | $5.51M | (m) | 9.35× |
| 2024-06-30 | $457.12M | $37.30M | $170.67M | $273.96M | (m) | (m) | $12.94M | (m) | 12.25× |
| 2024-03-31 | $395.36M | $30.89M | $51.04M | $333.82M | (m) | (m) | $5.78M | (m) | 12.80× |
| 2023-12-31 | $459.12M | $37.08M | $83.16M | $365.54M | (m) | (m) | $5.90M | (m) | 12.38× |
| 2023-09-30 | $473.45M | $37.49M | $69.25M | $396.26M | (m) | (m) | $6.21M | (m) | 12.63× |
| 2023-06-30 | $502.10M | $54.58M | $154.76M | $337.20M | (m) | (m) | $10.23M | (m) | 9.20× |
| 2023-03-31 | $481.46M | $59.40M | $109.93M | $361.29M | (m) | (m) | $14.69M | (m) | 8.11× |
| 2022-12-31 | $528.82M | $53.73M | $61.90M | $455.42M | (m) | (m) | $13.89M | (m) | 9.84× |
| 2022-09-30 | $569.06M | $48.08M | $74.36M | $477.87M | (m) | (m) | $11.04M | (m) | 11.84× |
| 2022-06-30 | $513.03M | $44.18M | $96.04M | $394.45M | (m) | (m) | $9.71M | (m) | 11.61× |
| 2022-03-31 | $469.74M | $36.62M | $84.51M | $364.54M | (m) | (m) | $8.71M | (m) | 12.83× |
| 2021-12-31 | $471.32M | $47.91M | $173.31M | $283.99M | (m) | (m) | $10.26M | (m) | 9.84× |
| 2021-09-30 | $502.86M | $53.49M | $190.02M | $293.46M | (m) | (m) | $11.50M | (m) | 9.40× |
| 2021-06-30 | $602.17M | $46.00M | $223.50M | $364.20M | (m) | (m) | $11.01M | (m) | 13.09× |
| 2021-03-31 | $716.06M | $54.85M | $236.87M | $462.72M | (m) | (m) | $14.88M | (m) | 13.06× |
| 2020-12-31 | $845.13M | $94.32M | $183.35M | $644.56M | (m) | (m) | $10.39M | (m) | 8.96× |
| 2020-09-30 | $854.06M | $50.13M | $158.14M | $682.89M | (m) | (m) | $10.15M | (m) | 17.04× |
| 2020-06-30 | $909.58M | $40.90M | $280.38M | $619.27M | (m) | (m) | $9.06M | (m) | 22.24× |
| 2020-03-31 | $504.41M | $26.82M | $135.90M | $357.03M | (m) | (m) | $7.20M | (m) | 18.81× |
| 2019-12-31 | $544.58M | $33.08M | $175.13M | $355.41M | (m) | (m) | $9.25M | (m) | 16.46× |
| 2019-09-30 | $509.76M | $33.35M | $160.99M | $340.25M | (m) | (m) | $8.05M | (m) | 15.28× |
| 2019-06-30 | $511.54M | $38.00M | $112.58M | $389.84M | (m) | (m) | $23.50M | (m) | 13.46× |
| 2019-03-31 | $476.63M | $27.27M | $92.75M | $373.39M | (m) | (m) | $12.98M | (m) | 17.48× |
| 2018-12-31 | $467.98M | $29.46M | $92.43M | $366.95M | (m) | (m) | $12.34M | (m) | 15.89× |
| 2018-09-30 | $247.35M | $159.48M | $83.14M | (m) | (m) | (m) | $3.08M | (m) | 1.55× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |